Ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic #lupus erythematosus - a between group difference of 29%. Article in @TheLancet https://t.co/kic3xAfHcE #EULAR2019 #LancetRheumatology https://t.co/Wizel4nnSk